Eli Lilly, the drugmaker of Zepbound, has announced that their popular weight loss drug may also be beneficial for individuals with obstructive sleep apnea. Obstructive sleep apnea is a condition characterized by brief pauses in breathing during sleep, leading to disrupted sleep patterns and potential health risks such as heart disease and stroke.
Recent trials have shown promising results, prompting Eli Lilly to consider seeking FDA approval to expand the use of Zepbound to include the treatment of obstructive sleep apnea. The drug, which contains tirzepatide as its active ingredient, was initially approved for obesity treatment and later for type 2 diabetes.
